文献速递物质与行为成瘾

哌唑嗪治疗酒精使用障碍的双盲随机临床试验

Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.
PubMed 文献 · Am J Psychiatry · 2018-08-29

哌唑嗪组困倦和水肿报告率更高,提示其作为减害药物具有前景。

要点

  • 哌唑嗪组每周饮酒量和重度饮酒天数随时间下降更快。
  • 哌唑嗪组困倦和水肿报告率高于安慰剂组。
  • 哌唑嗪可作为酒精使用障碍的减害药物候选,需独立验证。

核心结论

  • 哌唑嗪作为酒精使用障碍的减害药物治疗具有前景,值得独立研究组进一步评估。

研究设计与样本

  • 药物滴定至第2周末目标方案为晨4 mg、下午4 mg、睡前8 mg,行为平台为医疗管理。
  • 参与者提供每日饮酒数据,采用广义线性混合效应模型分析。

主要发现

  • 每周饮酒量和每周重度饮酒天数均显示条件与周次的显著交互作用,哌唑嗪组随时间下降更快。
  • 哌唑嗪组困倦和水肿报告率高于安慰剂组。

临床怎么用

  • 哌唑嗪可能作为酒精使用障碍的减害选择,但需关注困倦和水肿不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Current medications for alcohol use disorder do not target brain noradrenergic pathways. Theoretical and preclinical evidence suggests that noradrenergic circuits may be involved in alcohol reinforcement and relapse. After a positive pilot study, the authors tested the α-1 adrenergic receptor antagonist prazosin to treat alcohol use disorder in a larger sample. METHOD: Ninety-two participants with alcohol use disorder but without posttraumatic stress disorder were randomly assigned to receive prazosin or placebo in a 12-week double-blind study. Medication was titrated to a target dosing schedule of 4 mg in the morning, 4 mg in the afternoon, and 8 mg at bedtime by the end of week 2. The behavioral platform was medical management. Participants provided daily data on alcohol consumption. Generalized linear mixed-effects models were used to examine the impact of prazosin compared with placebo on number of drinks per week, number of drinking days per week, and number of heavy drinking days per week. RESULTS: Eighty participants completed the titration period and were included in the primary analyses. There was a significant interaction between condition and week for both number of drinks and number of heavy drinking days, such that the rate of drinking and the probability of heavy drinking showed a greater decrease over time for participants in the prazosin condition compared with those in the placebo condition. Participants in the prazosin condition were more likely to report drowsiness and edema than participants in the placebo condition. CONCLUSIONS: Prazosin holds promise as a harm-reduction pharmacologic treatment for alcohol use disorder and deserves further evaluation by independent research groups.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Simpson TL, Saxon AJ, Stappenbeck C, et al. Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. Am J Psychiatry. 2018. PMID: 30153753. doi:10.1176/appi.ajp.2018.17080913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。